Sarepta Therapeutics Inc

NASDAQ: SRPT
$130.90
+$4.24 (+3.3%)
Closing price May 1, 2024
Sarepta Therapeutics Inc is a pioneering biopharmaceutical company dedicated to developing unique treatments for rare diseases, with a strong focus on RNA-targeted therapies, gene therapies, and genetic therapeutic modalities. It is known for producing EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, targeting duchenne muscular dystrophy among other conditions. The company is actively working on advancing its pipeline, including SRP-5051 and SRP-9003 for muscular dystrophies. Founded in 1980 and based in Cambridge, Massachusetts, Sarepta collaborates with leading institutions to push the boundaries of genetic medicine.

Wednesday's Top Analyst Upgrades and Downgrades: Alcoa, Caesars, Chevron, DraftKings, Lucid, SoFi, Wynn Resorts and More
Wednesday’s top analyst upgrades and downgrades included Alcoa, Caesars Entertainment, Chevron, DraftKings, Lucid, Sarepta Therapeutics, SoFi Technologies and Wynn Resorts.
Lee Jackson
Published:

Thursday's Top Analyst Upgrades and Downgrades: Chewy, Eli Lilly, Etsy, Halliburton, Robinhood, Roku, Walmart, Western Digital and More
Thursday’s top analyst upgrades and downgrades included Avis Budget, Chewy, Danaher, Eli Lilly, Etsy, Fastly, Halliburton, Robinhood, Roku, Walmart and Western Digital.
Lee Jackson
Published:

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
Chris Lange
Published:

Monday's Top Analyst Upgrades and Downgrades: Best Buy, Discover Financial, Dollar General, Etsy, HCA, KeyCorp, Simon Property, ViacomCBS and More
Monday's top analyst upgrades and downgrades included Best Buy, Discover Financial, Dollar General, Etsy, HCA Healthcare, KeyCorp, Simon Property, ViacomCBS and Weyerhaeuser.
Lee Jackson
Published:

Top Analyst Upgrades and Downgrades: Aflac, CME, Chevron, CVS, DR Horton, Goodyear, Lam Research, Micron, US Steel and More
Friday's top analyst upgrades and downgrades included Aflac, CME, Chevron, CVS Health, D.R. Horton, Goodyear Tire and Rubber, Lam Research, Micron Technology and U.S. Steel.
Lee Jackson
Published:

Top Analyst Upgrades and Downgrades: Crocs, Gap, GW Pharma, Lowe's, Merck, Nio, Palo Alto, Phillips 66, Starbucks, Vital Farms and More
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Jon C. Ogg
Published:

How Sarepta and Selecta Bio Are Taking the Fight to DMD
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Chris Lange
Published:

Biotech Stocks Seeing the Biggest Boost From Coronavirus Outbreak
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
Chris Lange
Published:

China's Coronavirus Could Prompt Buying Frenzy in These Biotech Stocks
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Chris Lange
Published:

Why One Analyst Sees Sarepta's Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this...
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron, Sarpeta and More
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
Jon C. Ogg
Published:

Why This Duchenne Muscular Dystropy Deal Could Be Huge
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Chris Lange
Published:

Sarepta Catches a Big Break With Duchenne Muscular Dystrophy Drug
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap, Wayfair and More
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Jon C. Ogg
Published:
Last Updated:

Top Analyst Upgrades and Downgrades: Arista, Booking, Dunkin, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square, YETI and More
Friday's top analyst upgrades, downgrades and initiations included Arista Networks, Booking, Dunkin' Brands, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square and YETI.
Jon C. Ogg
Published: